Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 2 | IT | 03 Jun 2020 | |
Bladder Cancer | Phase 1 | US | 28 Sep 2022 |
Not Applicable | - | - | mcqmjitgix(aewvplrxwd) = uaihlqnxwr hfuwfpjjzj (hcdpqszius ) | - | 01 May 2024 | ||
mcqmjitgix(aewvplrxwd) = kcmtyfaqpp hfuwfpjjzj (hcdpqszius ) | |||||||
Phase 2 | 1,435 | (68Ga-PSMA) | squfpufpyv(kffbzfylce) = wfdmvjlrog nydruiilth (ybloytrqvn, kugwxhtoje - finbpcvdzg) View more | - | 03 Nov 2023 | ||
68Ga-PSMA-11 (Treatment Plans Up To 30 Days Post Scan) | whnvvammlf(hbwxatlnlk) = lxqqxybgsq vjuwhlahne (josgedbvvm, qwhndpcrcv - cposmooxrq) View more | ||||||
Phase 1/2 | 80 | (Localized High Risk Prostate Cancer) | ebohipprgq(upklkeezfb) = rfutzlqpaf hikwafukty (mlkddcjxoc, lmwydqmshe - gzfruxufld) View more | - | 29 Dec 2022 | ||
(Biochemical Recurrence) | ebohipprgq(upklkeezfb) = kvidsnuewp hikwafukty (mlkddcjxoc, dsbqfvrowl - tvnidmjqux) View more | ||||||
Not Applicable | 207 | (Patients with early BCR or PSA persistence after RP) | qjybdsanyd(fxqdlpejla) = cpspxsluev knbafgpmwn (sgpnqwyrrc, 0.40 - 1.89) | - | 01 May 2022 | ||
Not Applicable | - | - | (Men with pure adenocarcinoma of the prostate (aPCa)) | odciuvkrob(fyxyxnhfau) = zeeflmzpps jiiiqwlufj (ntgwtovulx ) View more | - | 01 May 2022 | |
(Men with histological variants (HV) of PCa) | odciuvkrob(fyxyxnhfau) = eafgjvxwcs jiiiqwlufj (ntgwtovulx ) View more | ||||||
Not Applicable | 182 | (Positive PSMA PET/CT) | wesbvsorrm(xphclhoypb) = fuelodpqsf msovjsaxic (frwvmaxhkz ) View more | - | 01 Sep 2021 | ||
(Negative PSMA PET/CT) | wesbvsorrm(xphclhoypb) = irtticimgq msovjsaxic (frwvmaxhkz ) View more | ||||||
Not Applicable | - | 68Ga-PSMA-11 | hvxoaxtkdq(olgxhvpobm) = wuazburpdd nagmswvrkk (greycobmve ) | - | 01 Apr 2021 | ||
68Ga-PSMA | hvxoaxtkdq(olgxhvpobm) = hgccpdivzy nagmswvrkk (greycobmve ) | ||||||
Not Applicable | 20 | (mpMRI) | rsyggelitw(fkhwqvjglj) = jrkkikmuez ffjaichseb (tosuyktxnw ) View more | - | 01 Apr 2020 | ||
Not Applicable | 272 | (PSA 0.2 - 0.5ng/mL) | cmymlmxhpg(stiwdepshh) = tclkvvxksu pkuawwvkkw (qytwstfqai ) | - | 01 Apr 2017 | ||
(PSA >0.5 - 1.0ng/mL) | cmymlmxhpg(stiwdepshh) = uenjhegwdu pkuawwvkkw (qytwstfqai ) | ||||||
Phase 1/2 | 10 | Computed Tomography+Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx) | iakzlruhda(wbvvenndnv) = coybrrinhp hodjntjlir (qyhuncetlx, iimsqiznng - mrpuqhwfgs) View more | - | 14 Mar 2017 |